Plasma coenzyme Q10 in children and adolescents undergoing doxorubicin therapy

Abstract The objective of this study was to test the hypothesis that doxorubicin treatment for cancer in childhood and adolescence causes a dose-related decrease in the concentration of plasma coenzyme Q 10 . The concentration of plasma coenzyme Q 10 was measured before and after administration of doxorubicin in six patients, and before and after chemotherapy in six patients undergoing treatments that did not include doxorubicin. There was a significant increase in the concentration of plasma coenzyme Q 10 in post-treatment samples compared to pre-treatment samples in patients treated with doxorubicin ( P =0.008; n =32), whereas there were no significant changes in plasma coenzyme Q 10 concentrations in patients treated with chemotherapy that did not include doxorubicin. ( P =0.770; n =30). We hypothesise that the increase in plasma coenzyme Q 10 that was observed in patients undergoing doxorubicin treatment is due to release of coenzyme Q 10 from apoptotic or necrotic cardiac tissue. We conclude that the cardiotoxicity due to doxorubicin therapy does not involve acute myocardial depletion of coenzyme Q 10 .